Versa Vascular is developing the AdapTR transcatheter tricuspid repair device and a delivery platform designed to support native leaflet function while enabling repositioning, implant control, and atrial device positioning to simplify intraprocedural imaging. The company reported positive clinical results and is conducting a first-in-human study outside the U.S. and planning a U.S. Early Feasibility Study. Versa intends to use recent financing to complete those clinical programs and to continue product development and optimization. Leadership changed as part of the update: longtime Medtronic structural heart executive Bill Shields was named CEO, succeeding David Hovda, who will remain as an advisor. Shields brings experience leading transcatheter mitral and tricuspid programs and product development and clinical studies. The article did not disclose revenue, user metrics, founding year, or location.

Total raised

$42M

Funding rounds

2

Latest round

Series C

Latest activity

Aug 2026